Stockscreener 앱 받기
76.57
0.05%
0.07
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
Biotech Growth makes 14-times return on Forte Biosciences accepting $2.2bn bid from Argenx SE - QuotedData
argenx signs agreement to buy Forte Biosciences for $2.2bn - Pharmaceutical Technology
Barclays cuts Forte Biosciences stock rating on acquisition terms By Investing.com - Investing.com Canada
Barclays cuts Forte Biosciences stock rating on acquisition terms - Investing.com
Forte Biosciences (FBRX) Stock Looks Stretched On Book Value Yet Strong On Pipeline Hope - simplywall.st
Biotech Growth Trust Notes $2.2 Billion Acquisition Of Forte Biosciences - DirectorsTalk Interviews
Forte Biosciences Inc (FBRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Why Did AAPL, FBRX, RTX Stocks Surge To 52-Week Highs Today? - TradingView
Dallas biopharmaceutical company to be acquired for over $2B - Dallas News
Why is Forte Biosciences stock surging nearly 40% today? By Investing.com - Investing.com UK
Argenx enters biotech buyer class with $2.2B Forte takeout - BioCentury
argenx (FBRX counterparty) plans full-share tender offer for Forte Biosciences - Stock Titan
Argenx’s $2B Forte Bio Acquisition Brings Autoimmune Playbook to Prevalent Disorders - MedCity News
The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today - Barchart.com
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx - Wilson Sonsini
Argenx to acquire Forte Biosciences for $2.2 billion - Drug Discovery News
Forte Biosciences agrees to $2.2 billion buyout - The Business Journals
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Forte Biosciences, Inc. (NASDAQ: FBRX) - Morningstar
Argenx to Acquire Forte Biosciences for $2.2 Billion, Bolstering Immunology Pipeline with Promising Anti-CD122 Antibody - finance.biggo.com
Shareholder Alert: Ademi LLP investigates whether Forte Biosciences, Inc. is obtaining a Fair Price for Public Shareholders - Morningstar
Forte: 'Hold' On Positive FB102 Vitiligo Treatment Data And argenx Acquisition For $2.2 Billion - Seeking Alpha
Argenx Buys Forte Biosciences for $2.2B to Boost Pipeline - Briefs Finance
Stocks making the biggest moves midday: ASML, SK Hynix, SAP, Forte Bio, Brown-Forman & more - CNBC
Argenx to buy Forte Biosciences for about $2.2 billion - 95.7 KELO-FM
FBRX Stock Extends Surge As Barclays Lifts Target On FB102 Momentum - StocksToTrade
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B - Proactive financial news
Argenx expands immune pipeline in $2.2B cash acquisition of Forte - BioWorld News
Argenx (ARGX) to Acquire Forte Biosciences for $2.2 Billion - GuruFocus
argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX) - Seeking Alpha
argenx Expands Immunology Pipeline with Forte Biosciences Acquis - GuruFocus
Forte Biosciences Inc (FBRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
argenx to Acquire Forte Biosciences for $2.2 Billion, Adding Anti-CD122 Antibody FB102 - BioPharm International
Forte Biosciences Surges on $2.2 Billion Cash Buyout Deal - Quiver Quantitative
argenx boosts immuno expertise with buy of Forte Biosciences - The Pharma Letter
Baker Hughes Posts Upbeat Q2 Earnings, Joins Forte Biosciences, Eikon Therapeutics And Other Big Stocks M - Benzinga
Argenx to acquire Forte Biosciences for $2.2B - Axios
argenx to Acquire Forte Biosciences for $77.00 Per Share in Cash Deal - Kalkine Media
argenx SE (ARGX) to Acquire Forte Biosciences (FBRX) for $2.2B - GuruFocus
argenx to Acquire Forte Biosciences for $2.2 Billion - Contract Pharma
FBRX Stock Extends Rally As Barclays Lifts Biotech Hopes - StocksToTrade
Argenx (ARGX.US) makes a bold $2.2 billion acquisition of Forte Biosciences (FBRX.US) at a 40% premium, strengthening its immunology drug portfolio. - Bitget
argenx Acquires Forte Biosciences for $2.2 Billion - Pharmaceutical Executive
FBRX Stock Surges As Barclays Backs FB102 Breakthrough - timothysykes.com
argenx to buy Forte Bio for $2.2B in immunology push - FirstWord Pharma
Freshfields-Led Drug Co. To Buy Forte Biosciences For $2.2B - Law360
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal By Investing.com - Investing.com Canada
TD Cowen downgrades Forte Biosciences stock rating on Argenx deal - Investing.com
argenx to Acquire Forte Biosciences in $2.2 Billion Deal to Expand Autoimmune Pipeline - citybiz
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy - BioSpace
argenx To Acquire Forte Biosciences For $2.2 Billion, Adding Anti-CD122 Antibody FB102 To Immunology Pipeline - Pulse 2.0
Forte Biosciences stock surges 39% on argenx acquisition deal By Investing.com - Investing.com India
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Stocks making the biggest moves premarket: Micron Technology, Forte Biosciences, ExxonMobil, Baker Hughes & more - CNBC
Argenx to acquire Forte in $2.2B deal for ‘differentiated’ immune drug - Yahoo Finance
Forte Biosciences stock surges 39% on argenx acquisition deal - Investing.com
FBRX Stock On Track For Highest Levels In Over 4.5 Years As ArgenX Scoops Up Autoimmune Drug Maker - Stocktwits
Forte Biosciences Agrees to Be Acquired by Argenx in $2.2 Billion Deal - marketscreener.com
Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx - Yahoo Finance
Argenx agrees $2.2 billion acquisition of Forte Biosciences to strengthen autoimmune drug pipeline - Yahoo Finance
Updated: Argenx to pick up autoimmune biotech Forte Biosciences for $2.2B - Endpoints News
Forte Biosciences to be acquired by argenx - TipRanks
Argenx pens $2.2bn deal to buy autoimmune biotech Forte - pharmaphorum
Forte Biosciences to Be Acquired by argenx in $77-Per-Share Tender Offer and Merger - TradingView
Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug - Fierce Biotech
argenx to acquire Forte Biosciences (Nasdaq: FBRX) in $2.2B all-cash deal - Stock Titan
argenx (Nasdaq: ARGX) to acquire Forte Biosciences in $2.2B cash tender offer - Stock Titan
Forte surges in premarket as Argenx agrees $2.2 billion acquisition By Investing.com - Investing.com Canada
Argenx To Buy Forte Biosciences For $2.2bn, Adds Clinical-Stage CD122 Autoimmune Asset - insights.citeline.com
0.96%
0.92%
자본화:
|
볼륨(24시간):